Oncology and Regenerative Medicine

Oncology and Regenerative Medicine

Cancer is a leading cause of death worldwide; annual cancer cases are expected to rise by 70 percent over the next two decades, according to the World Health Organization.

This growing global impact has led to widespread efforts in the medical and scientific community to decrease cancer’s mortality rate and increase treatment options and efficacy. Within the regenerative medicine and advanced therapies sector, companies are employing cell- and gene-based cancer therapies to combat various forms of cancer.

Adoptive T cell therapies – ex vivo

• CAR-T cell therapy
• T Cell Receptors (TCRs)
• Antibody-coupled T Cell Receptor (ATCR)
• Natural Killer “NK” Cells
• Tumor-Infiltrating Lymphocytes (TILs)
• Marrow-Infiltrating Lymphocytes (MILs)

Cancer vaccines – dendritic and other antigen-presenting constructs

• Dendritic cell vaccines
• Artificial antigen-presenting cells
• mRNA transfected dendritic cells
• Other viruses or bacteria that can be used to stimulate an immune response (Vaccinia, Listeria)

Oncolytic Viruses

• Retroviral replicating vectors (RRVs)
• T-Vec Re-engineered herpes simplex virus
• Oncolytic virus platform